Blog

ESMO Daily Reporter Interviewed Paolo Tarantino on ADCs in Breast Cancer Care

ESMO/LinkedIn

Jun 12, 2025, 18:30

ESMO Daily Reporter Interviewed Paolo Tarantino on ADCs in Breast Cancer Care

ESMO – European Society for Medical Oncology shared a post on LinkedIn:

“Recent study results support the integration of Antibody Drug Conjugates (ADCs) into the first-line treatment for metastatic Breast Cancer.

Read the opinion by Paolo Tarantino in the ESMO Daily Reporter anylsing how the results from these key studies will impact the treatment course and what pending questions remain to be addressed.”

Paolo Tarantino, 2025 Yvonne’s Top Voice’ Award Winner, Research Fellow at Dana-Farber Cancer Institute, shared this post, adding:

“Multiple positive trials, one common feature: advancing the use of ADCs to earlier lines of treatment.

It’s happening fast, and it is producing meaningful clinical benefits. Yet, questions remain.

Thank you ESMO Daily for this interview!”

More posts featuring ESMO on OncoDaily.

ADCs Antibody drug conjugates Breast Cancer cancer Dana-Farber Cancer Institute ESMO ESMO Daily Reporter European Society for Medical Oncology OncoDaily Oncology Paolo Tarantino

Linda Evangelista and Breast Cancer: How She Went Against, How She Survived, and More

Agenus Enters New Era With $141M Zydus Deal Signaling Strategic Transformation in Immuno-Oncology

Oncologist Near Me – Yelena Janjigian: A Global Leader in Gastrointestinal Oncology

How Artificial Intelligence Is Transforming Cancer Care in 2025: Diagnosis, Treatment, Clinical Trials, and Screening

Inside ASCO25 Exhibition - Who did it the best?